Introduction
Parkinson's disease (PD), first described by James Parkinson in 1817 in his work, An Essay on the Shaking Palsy, is the second most common age-related, progressive neurodegenerative disorder after Alzheimer's disease (AD). The majority of cases are of idiopathic origin. However, a number of specific genetic mutations causing PD have been discovered.
Clinically, it is characterized by a triad of cardinal neurological symptoms including bradykinesia, muscular rigidity, resting tremor and postural instability that become apparent when more than 60% of the melanised dopaminergic neurons of the substantia nigra pars compacta (SNpc) have degenerated and 80% of the striatal dopamines are lost (Bernheimer et al., 1973; Hoehn and Yahr, 1967) .
Presence of ubiquitylated intraneuronal protein inclusions enriched in a-synuclein (aSyn) in the cytoplasm of neurons (Lewy bodies) and thread-like proteinacious inclusions within neurites (Lewy neurites), are one of the neuropathological hallmarks invariably associated with idiopathic PD as well as familial PD (Spillantini et al., 1997) .
In addition to PD, aSyn also plays an important role in the pathogenesis of dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), comprising a disease concept, known as asynucleinopathies, characterized by abnormal accumulation of aggregates of aSyn protein in neurons, nerve fibres or glial cells.
However, the distinct set of symptoms, prognosis and management issues for each synucleinopathy has given the term little practical value as a diagnostic term for the clinicians.
Structure and function of aSyn
aSyn is a 140 amino-acid acidic protein of 19 kDa originally isolated from amyloid plaques of Alzheimer's disease brains, as a fragment known as the precursor of the non-Ab-component (NACP) (Ueda et al., 1993) . It is widely expressed in various brain regions including the neocortex, hippocampus, dentate gyrus, olfactory bulb, thalamus, cerebellum, amygdala and nucleus accumbens and is predominantly localised in the presynaptic terminals (Iwai et al., 1995) . Structurally, aSyn comprises three overlapping regions including (1) the N-terminal repeat region, residues 1e95; (2) the highly hydrophobic central portion, residues 61e95 and (3) the acidic C-terminal region, residues 96e140 (George et al., 1995) ( Fig. 1 ).
The positively charged N-terminal region is dominated by seven imperfect 11-residue repeats, each with the core consensus sequence motif KTKEGV that contribute to this domain's structural apolipoprotein-like class-A2 amphipathic a-helical features (George et al., 1995) . This region also harbors one of two conserved Fatty Acid Binding Protein (FABP) signatures (residues 2e19), which are important for lipid binding (Perrin et al., 2000; Sharon et al., 2001 ).
Most likely, this domain is responsible for aSyn to form a stable helical structure in association with lipid micelles, for the weak association of aSyn with synaptic vesicles and for its bilayer disrupting capacity (Dev et al., 2003) . All familial mutations (A30P, E46K, H50Q, G51D, A53E and A53T) that are related to the autosomal dominant form of PD cluster in this region (Lundvig et al., 2005) .
The central portion, known as non-Ab-component (NAC) region, comprises the highly amyloidogenic part (Ueda et al., 1993) and serves as the building block of aSyn aggregates with critical residues within the GAV motif (residues 66e74) (Du et al., 2003) . It is responsible for the ability of aSyn (i) to undergo a conformational change from random coil to b-sheet structure (Serpell et al., 2000) , (ii) to form cylindrical b-sheets (Perutz et al., 2002) , and (iii) to form amyloid-like protofibrils and fibrils (El-Agnaf and Irvine, 2000) .
These features distinguish aSyn from its two close relatives, b-and g-Syn, which fail to form copolymers due to their lack of most NAC sequence (Biere et al., 2000) .
The negatively charged C-terminal region is found to remain free and unfolded, and does not associate with vesicles or micelles by NMR spectroscopy studies (Eliezer et al., 2001) . However, it is one of the two regions in aSyn (residues 123e140) that show sequence resemblance with cytosolic FABP (Sharon et al., 2001) . Furthermore, the C-terminal region seems to play a role in preventing aSyn aggregation as C-terminal-region-truncated form of aSyn (residues 1e120) was reported to be more prone in forming filaments than the full-length protein (Crowther et al., 1998; Li et al., 2005) . Interactions between C-terminal and N-terminal or central NAC region maintain the stable natively unfolded structure of aSyn, and consequently prevent aSyn from changing to intermediate conformations, which are required for aggregation and fibrillation (Hong et al., 2011) . The acidic C-terminal tail of aSyn also appears critical for its chaperone-like activity (Souza et al., 2000b) as C-terminal deletion leads to abolishment of chaperone activity and the second acidic repeat (residues 125e140) of aSyn has been suggested to be important for the chaperone activity (Kim et al., 2002) . Modifications of this second repeat region are implicated in the aggregation process of aSyn. Phosphorylation of Ser129 or nitration of Tyr125, Tyr133, and Tyr136 promote the formation of aSyn filaments or oligomers (Fujiwara et al., 2002; Giasson et al., 2000; Souza et al., 2000a) . Conversely, phosphorylation of Ser87 and Tyr125 has been reported in inhibiting aSyn fibrillization in vitro (Chen et al., 2009; Paleologou et al., 2010) (Fig. 1) .
In neurons, aSyn exists in equilibrium between cytosolic and membrane-bound states. Cytosolic aSyn has a natively unfolded monomeric state with no significant secondary structure, whereas membrane-bound aSyn adopts an a-helical multimeric conformation (Weinreb et al., 1996; Burr e et al., 2014) . In contrast to these intermediates and protofibrils and then to the characteristic bsheet-rich structure and crossed b-conformation in highly organized amyloid-like fibrils and finally deposition into Lewy bodies (Wood et al., 1999; Lashuel et al., 2002) (Fig. 2) . The fibrillization process of aSyn is reversible as aSyn fibrils disaggregate into monomeric and oligomeric species under near-physiological conditions when monomers are removed (Cremades et al., 2012) . Accumulating evidence has brought up the oligomer hypothesis that implicates oligomers as the main culprit for aSyn toxicity (Winner et al., 2011; Rockenstein et al., 2014) (Please see review of Ono, 2017) . Oligomers can be categorized into toxic "on-pathway" or non-toxic "off-pathway" to amyloid fibril formation (Cremades et al., 2012; Lorenzen et al., 2014) . Toxicity is likely related to the extent of internal b-sheet structure and exposure of hydrophobic surfaces. Toxic oligomers are usually b-rich and exposed more hydrophobic residues, which allowed them to permeabilize the membrane, in contrast to non-toxic oligomers (Celej et al., 2012; Campioni et al., 2010) . On the other hand, some studies suggest that fibrils can participate to a greater extent in mechanisms of toxicity compared to oligomers (Pieri et al., 2012) . Fine structural analysis of Lewy bodies in postmortem PD human brain tissue using synchrotron FTIR micro-spectroscopy has revealed abundance of b-sheet-rich structure, which is higher in the halo than in the core, which contains a large amount of proteins and lipids (Araki et al., 2015) .
Despite the long focus on aSyn, its exact normal function still remains unclear. General functions ascribed to aSyn include modulation of physiological processes such as neuronal plasticity, synaptic vesicle pool maintenance, dopamine metabolism, as well as in soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-complex assembly critical for neurotransmitter release, vesicle recycling and synaptic integrity.
Due to its high expression in presynaptic terminals, involvement of aSyn in synaptic plasticity has long been envisaged. aSyn was specifically up-regulated in a discrete population of presynaptic terminals of the songbird brain during a period of song-acquisitionrelated synaptic rearrangement (George et al., 1995) . On the other hand, aSyn showed a trend towards being down-regulated at the mRNA level following long-term potentiation in hippocampus of young and aged rats (Stephan et al., 2002) . Following prolonged repetitive stimulation, mice lacking aSyn exhibited attenuated synaptic response. Hippocampal synapses of aSyn knock-out mice showed fewer synaptic vesicles, particularly in the reserve pool, and the replenishment of docked vesicles by reserve pool vesicles after depletion was also slower, compared to that of their control littermates, suggesting that aSyn may be required for the genesis and/or maintenance of a reserve pool of presynaptic vesicles and regulation of synaptic vesicle mobilisation at nerve terminals (Murphy et al., 2000; Cabin et al., 2002) .
Specifically, aSyn may be instrumental in the physiological maintenance of dopamine homeostasis and dopamine synaptic tone in dopaminergic neurons of SNpc through regulation of the functional activity of tyrosine hydroxylase (TH) and dopamine transporter (DAT), as extensively reviewed (Lotharius and Brundin, 2002; Perez and Hastings, 2004; Sidhu et al., 2004a) . Dopamine biosynthesis begins with a rate-limiting step: the hydroxylation of tyrosine into dihydroxyphenylalanine (L-DOPA) catalysed by phosphorylated TH followed by conversion of L-DOPA into dopamine by aromatic amino acid decarboxylase. Since TH is only active in phosphorylated form, the regulation of TH phosphorylation/dephosphorylation is essential in dopamine biosynthesis (Perez and Hastings, 2004; Sidhu et al., 2004b) . TH has been reported to require binding of chaperone protein, 14-3-3 for optimal activation through maximal phosphorylation (Xu et al., 2002) . Conversely, aSyn directly binds to the dephosphorylated Fig. 2 . Fibril-formation pathway of aSyn. aSyn occurs physiologically as a natively unfolded monomer. Upon binding to membrane, aSyn adopts a-helical conformation. Under pathological conditions, misfolded aSyn assemblies form intermediates including oligomers and protofibrils before developing into fibrils and intracellular inclusion Lewy body. Oligomers can be categorized into toxic "on-pathway" or non-toxic "off-pathway" to amyloid fibril formation. Toxicity of oligomers is likely to correlate with the levels of b-sheet secondary structure. The assembly process can be reversed whereby fibrils disaggregate to form oligomers and monomers. Blue: Little or no b-structure; Orange: High b-structure.
(For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) form of TH and tends to maintain TH in an inactive form in an opposite manner to 14-3-3 proteins, causing an overall net decrease in enzymatic activity and dopamine synthesis (Perez et al., 2002) . In agreement, aging-associated increases in aSyn expression in the SN correlate to reduced TH expression (Chu and Kordower, 2007) . Dopamine transporter (DAT) is expressed in the presynaptic terminals of dopaminergic neurons where it mediates the reuptake of dopamine back into the dopaminergic nerve terminals (Chen and Reith, 2000) . Enhanced DAT activity would increase intracellular levels of dopamine with a resulting increased oxidative stress within the dopaminergic neuron and neuronal death. The regulation of DAT which involve the rapid and transient shuttling of the transporter molecule to and from the plasma membrane may thus be a key component in the maintenance of dopaminergic neurotransmission and the integrity of dopaminergic neurons (Sidhu et al., 2004a) . A study demonstrated that aSyn acts as the negative modulator of DAT activity whereby the transporter was dynamically trafficked away from the plasma membrane into the cytoplasm in the presence of wild type aSyn (Wersinger et al., 2003) . In addition, aSyn affects vesicular monoamine transporter-2, a transport protein integrated into the membrane of synaptic vesicles of presynaptic neurons acting to transport monoamine neurotransmitters into the vesicles. aSyn overexpression inhibits VMAT2, thereby interrupting dopamine homeostasis by causing increased cytosolic dopamine levels. Overall, dopaminergic neurons may have a higher need for aSyn function, and also a higher susceptibility to aSyn dysregulation.
SNAREs are protein complex consisting of synaptobrevin, syntaxin, and SNAP25, which play a role in vesicle priming, transferring of docked vesicles into an exocytosis-competent state, and vesicle fusion to the membrane (Goda, 1997) . aSyn directly bound to the SNARE-protein synaptobrevin-2/vesicle-associated membrane protein 2 (VAMP2) and promoted SNARE-complex assembly. Triple-knockout mice lacking synucleins developed age-dependent neurological impairments, exhibited decreased SNARE-complex assembly, and died prematurely (Burr e et al., 2010) . aSyn also regulate synaptic vesicle recycling by assisting in the folding and refolding of SNAREs (Bonini and Giasson, 2005) . In the synapse, aSyn promptly organizes into physiological multimers which cluster synaptic vesicles, restricting their trafficking. This may increase the local concentration of synaptic vesicles and also the SNARE protein synaptobrevin-2, thereby potentiates the formation of SNARE-complexes. Mice with homozygous knock-in gene encoding unphosphorylatable S187A-substituted SNAP-25 displayed abnormally condensed synaptic vesicles with concomitant mislocalization of aSyn protein to the periactive zone in the glutamatergic nerve terminals in striatum (Nakata et al., 2012) . Overall, the effect of aSyn on neurotransmitter release is by affecting the spatial organization of distinct synaptic pools within the presynaptic terminals (Wang et al., 2014; Burr e et al., 2010) .
Understanding structure and function of aSyn has implications in deciphering the molecular basis of synucleinopathies and in considering strategies to address aSyn aggregation.
aSyn propagation and Braak hypothesis
It is still debatable whether Lewy bodies and Lewy neurites are themselves neurotoxic or bystanders of another primary pathophysiological process (Jellinger, 2009 ), but their occurrence marks the presence of the disease. Lewy body pathology is not restricted to the SNpc but can also be found in other brain regions and in the peripheral autonomic nervous system as the disease progresses. The Braak's Staging of PD brain pathology provides useful information about staged distribution of Lewy bodies or aSyn deposition, with later stages correlating with clinical aspects of the disease. In this hypothesis, aSyn deposits begins from the lower brainstem or olfactory bulb, spreads rostrally and reaches to parkinsonism-causing SN and finally to the cerebral cortex. The concept attracted much attention, as it seems to explain the clinical course of PD from prodromal phase to PD with dementia (Braak et al., 2003) . Nevertheless, the predictive validity remains obscure with numerous observations being made in population of aged individuals showing brain synucleinopathy ranging up to Braak stages 4e6 at postmortem despite having no neurologic signs (Burke et al., 2008) .
Following the proposal of Braak hypothesis, several experimental findings and clinical observations have strengthened the notion that aSyn propagation which contributes to the anatomical spread of Lewy pathology, proving the theory correct. The first supporting evidence surfaced when a series of autopsies of PD patients who had received transplants of healthy embryonic neurons over one decade earlier developed characteristic aSyn and ubiquitin-positive Lewy bodies in a subset (2e5% over 5 years) of the grafted neurons Kordower et al., 2008a Kordower et al., , 2008b Li et al., 2008; Li et al., 2010) . Studies on PD patients dying sooner within 1e5 years after transplant surgery did not reveal any protein aggregates in the grafted neurons, showing that Lewy bodies develop slowly or with a long delay in previously healthy embryonic neurons. These data suggest host-to-graft disease propagation.
Evidence that aSyn transfers between neurons have then arisen from both in vitro and in vivo studies. Lee et al. (2008) reported that extracellular fibrillar and non-fibrillar oligomeric aggregates were internalized into neuronal cells via endocytosis while monomeric aSyn directly translocated across the plasma membrane. Another study reported that GFP-tagged aSyn oligomers added to culture media can be internalized by primary cortical neurons engineered to express aSyn tagged with red fluorescent protein and induce the formation of inclusion bodies in the cytoplasm of the recipient cells, suggesting that the internalized protein can act as a seed to recruit endogenous aSyn into aggregates (Danzer et al., 2009 ). Mouse neural stem cells tagged with GFP were reported to develop intracellular aSyn immunoreactivity and occasional aSynpositive inclusion bodies when injected into the hippocampus of aSyn transgenic mice ). These studies suggest that host-derived aSyn can enter transplanted neural cells and trigger aSyn aggregation and deposition, analogous to the findings in grafted PD patients. Taken together, results from human autopsies, cell cultures and transgenic mice suggest that intercellular aSyn transfer can contribute to the spreading of neuropathology in PD, which could explain why the pathology progresses stereotypically in accordance with Braak stages.
Many neurodegenerative diseases other than PD also share this common feature, the accumulation of protein aggregates, including neurofibrillary tangles comprised of amyloid beta (Ab) and tau in Alzheimer's disease (AD), huntingtin aggregates in Huntington's disease (HD) and prion in transmissible spongiform encephalopathy. These aggregation-prone proteins that were once thought to be distinct to one neurodegenerative disorder frequently coexist in disease brain, raising the possibility of cross seeding of one amyloidogenic protein by aggregated states of unrelated proteins.
Ab and aSyn fibrils and oligomers have been shown to act as seeds and affected each other's aggregation pathways in vitro. aSyn fibrils have greater seeding effect than those of oligomers and Ab (Ono et al., 2012b) . aSyn fibrils can also directly cross-seed tau fibrillization (Guo et al., 2013; Waxman and Giasson, 2011) . Moreover, fibrillar aSyn is potent in cross-seeding prion protein misfolding and aggregation in vitro and the produced self-replicating prion states triggered transmissible prion diseases upon serial passaging in animals (Katorcha et al., 2017) . Although cross-seed effect of aSyn on huntingtin has not been evidently shown, aSyn and mutant huntingtin were found to co-deposit in HD postmortem brains and when co-overexpressed in vivo, produced a synergistic increase in neurotoxicity in Drosophila and mouse model (Poças et al., 2015; Tom as-Zapico et al., 2012; Corrochano et al., 2012) .
These findings revealed the ability of aSyn to function as seed and promote aggregation within and among species.
Immunotherapy targeting aSyn for PD
The discovery that aSyn can transmit from cell to cell in a prionlike fashion suggests that immunization might be a viable option for treatment. A growing body of evidence shows immunotherapy targeting aSyn holds great promise for reducing aSyn in the brain. The first paper describing active immunization against aSyn reported that aSyn transgenic mice vaccinated with full human aSyn protein displayed a reduction of accumulated aSyn in neurons and neurodegeneration. Antibodies produced by immunized mice recognized abnormal aSyn associated with the neuronal membrane and promoted the degradation of aSyn aggregates (Masliah et al., 2005) . Rats that were first vaccinated with recombinant aSyn and then given rAAV-aSyn in the SN showed less aSyn inclusion in the striatum in association with regulatory T cell recruitment compared with rats given adjuvant (Sanchez-Guajardo et al., 2013) . Austrian biotech company AFFiRiS developed short peptides-AFFITOPE ® s (AFFs) that do not elicit aSyn-specific T cell response using next-generation active vaccination technology. Active vaccination with AFF1, peptide that elicited the most specific response against aSyn, resulted in decreased accumulation of aSyn oligomers in axons and synapses, accompanied by reduced degeneration of TH fibers in the caudo-putamen nucleus and by improvements in motor and memory deficits in two different aSyn transgenic mouse models (Mandler et al., 2014) . Immunization of a transgenic mouse model of MSA, which expresses aSyn in oligodendrocytes, with AFF1 resulted in the production of specific antiaSyn antibodies that crossed into the central nervous system and recognized aSyn aggregates within glial cells, leading to decreased accumulation of aSyn, reduced demyelination in neocortex, sdtriatum and corpus callosum, and reduced neurodegeneration. These studies further validated the efficacy of vaccination with AFFITOPEs ® for ameliorating the neurodegenerative pathology in synucleinopathies (Mandler et al., 2015) . AFF1 was advanced to human testing as PD01A. AFFITOPE ® PD01A and PD03A are currently being assessed in Phase I clinical studies enrolling 32 and 36 early PD patients, respectively (ClinicalTrials.gov number, NCT01885494, NCT02267434). PD01A was safe and well-tolerated with an immune response seen in 86% of patients and the induced antibodies preferentially bind to aSyn fibrils, encouraging continued development.
Passive immunization using anti-human aSyn N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioural deficits in an AAV-aSyn rat model of PD (Shahaduzzaman et al., 2015) . Another aSyn N-terminal peptide antibody has been reported to reduce aSyn preformed fibrilsinduced LB/LN formation and rescue neuronal loss in cellular and mouse models by preventing both fibrils uptake and subsequent cell-to-cell transmission of pathology (Tran et al., 2014) . Passive immunization with the monoclonal antibody 9E4 against the Cterminus of aSyn ameliorates deficits in an aSyn transgenic model by promoting aSyn clearance . In the subsequent study, they tested the efficacy of novel monoclonal antibodies against the C-terminus truncation site of aSyn (1H7, 5C1, and 5D12) in the aSyn transgenic mouse model and found that, comparable to 9E4, immunotherapy with the 1H7 and 5C1, and to a lesser extent 5D12, attenuated synaptic and axonal pathology, reduced the accumulation of C-terminal-truncated aSyn in axons, rescued the loss of TH fibers in striatum, and improved motor and memory deficits (Games et al., 2013 (Games et al., , 2014 . In these studies, the proposal was that monomeric antibody enters into neurons and enhances degradation through autophagic/lysosomal pathway. There seems to be alternative mechanisms by which antibody reduces aSyn burden in brain. Bae et al. (2012) aSyn attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells by increasing expression levels of TH, DAT and VMAT2 and cell resistance to oxidative stress (Chen et al., 2013) . Nanoparticlesmediated delivery of aSyn targeting shRNA plasmid provide effective repair in a PD model in vitro and in vivo by inhibiting apoptosis (Niu et al., 2017) .
Recent advances in the antisense oligonucleotide (ASO) technology have enabled an alternative strategy for gene therapy using ASOs, facilitated by their remarkably widespread distribution and cellular uptake into the brain and muscles with high affinity, target specificity and stability. ASOs blocking target splice sites can modulate alternative splicing events and restore functional protein expression. This approach has been applied as a treatment for Duchenne muscular dystrophy and spinal muscular atrophy. ASOs cleaving target RNA by recruiting RNase H can reduce the expression of the toxic RNA or protein. These ASOs have been applied to treat myotonic dystrophy, HD, amyotrophic lateral sclerosis, and familial amyloid polyneuropathy. It is believed that ASO targeting aSyn is of potential disease modifying therapeutic use for PD and other synucleinopathies.
However, silencing of endogenous aSyn in adult rat SN leads to nigrostriatal degeneration and motor deficits (Gorbatyuk et al., 2010) . Another group also reported that when co-delivered into rat SN with AAV-aSyn, AAV harbouring shRNA or microRNA targeting aSyn protected against the forelimb deficit but displayed loss of striatal dopaminergic loss Khodr et al., 2011) . They found the same target sequence embedded in a microRNA30 transcript has low toxicity in vitro but in vivo study revealed the positive effect of AAV-mir30-hSNCA on forelimb behavior and SN DA neurons accompanied with inflammation and reduced TH expression (Khodr et al., 2014) . These data suggest that the extent of aSyn silencing should hence be carefully controlled, as its near complete loss may have adverse effect on dopaminergic cell function and integrity.
Small molecule and peptide inhibitors of aSyn
Small molecules are being tremendously explored for pharmacological suppression of aSyn aggregation and toxicity. A number of antioxidant polyphenols, nordihydroguaiaretic acid, curcumin, rosmarinic acid, ferulic acid, wine-related polyphenols (tannic acid, myricetin, kaempferol, (þ)-catechin and (À)-epicathechin) as well as vitamin and vitamin-like substances including vitamin A, betacarotene and coenzyme Q10 were reported to dose-dependently inhibit the formation of aSyn fibrils and destabilize preformed aSyn fibrils (Ono and Yamada, 2006; Ono and Yamada, 2007c) .
Phenolic compounds, myricetin and rosmarinic acid, were found to inhibit aSyn oligomerization and secondary structure conversion and thereby reduce the neurotoxicity of aSyn oligomers (Takahashi et al., 2015) . Polyphenol (À)-epigallocatechin gallate (EGCG) also efficiently inhibits the fibrillogenesis of aSyn by directly binding to the natively unfolded polypeptides, preventing their conversion into toxic, on-pathway aggregation intermediates and promoting formation of a new type of unstructured and non-toxic aSyn oligomers instead of b-sheet rich amyloid (Ehrnhoefer et al., 2008; Jha et al., 2017) . It was later reported that EGCG also dissembles preformed aSyn fibrils by converting large, mature aSyn and amyloidbeta fibrils into smaller, amorphous protein aggregates that are nontoxic to mammalian cells (Bieschke et al., 2010) . Baicalein, a typical flavonoid compound, can inhibit the formation of the aSyn oligomers, in vitro and in vivo (Zhu et al., 2004; Hu et al., 2016) . Taken altogether, these compounds with anti-fibrillogenic and antioxidant activities could be key molecules in developing therapeutic strategies targeting aSyn.
Prolyl oligopeptidase, a serine protease responsible for maturation and degradation of short neuropeptides and peptide hormones, can accelerate the aSyn aggregation process, while its inhibition by a small molecule inhibitor, 4-phenylbutanoyl-l-prolyl-2(S)-cyanopyrrolidine (KYP-2047), decreases aSyn oligomer formation and enhances its clearance via autophagy in aSyn overexpressing cell types and in transgenic PD animal models (Brandt et al., 2008; My€ oh€ anen et al., 2012; Svarcbahs et al., 2016) . Members of the FK506 binding protein (FKBP) family, the peptidyl-prolyl isomerases, were also shown to accelerate the aggregation of aSyn in vitro. FK506, a specific inhibitor of this family of proteins, inhibited aSyn aggregation and neuronal cell death in cellular and mouse model (Gerard et al., 2010) .
Cholesterol has been linked to a-synucleinopathies by recent work suggesting cholesterol metabolites appear to accelerate aSyn fibrillization (Bosco et al., 2006; Eriksson et al., 2017) . Cholesterol synthesis inhibitors, Lovastatin, Simvastatin and Pravastatin, and a cholesterol-extracting agent, methyl-beta-cyclodextrin, interfered with aSyn accumulation in models of a-synucleinopathy (Bar-On et al., 2006 Koob et al., 2010) . These results suggest that changes in cholesterol and lipid composition using cholesterollowering agents may be used as a tool for the treatment of synucleinopathies.
Heat shock protein 70 (Hsp70) is upregulated as part of a stress response to protein misfolding and aggregation and protects against misfolded aSyn-induced toxicity .
Geldanamycin, a naturally occurring benzoquinone ansamycin that induces Hsp70, has been shown to reduce aSyn-induced neurotoxicity in cellular and PD fly model Auluck et al., 2005) . In addition, pharmacological up-regulation of Hsp70 by Hsp90 inhibitors prevents a syn oligomerization and rescue toxicity (Putcha et al., 2010) .
With an inverse association between cigarette smoking and Parkinson's disease (PD), a study showed nicotine can dosedependently inhibit aSyn fibril formation and destabilize preformed aSyn fibrils (Ono et al., 2007a) . However, more information about tolerability and safety of nicotine administration are needed before its therapeutic use gets warranted.
Several studies have focused on drug repositioning through the discovery of novel clinical use for an existing drug approved for different indication. Anti-parkinsonian agents, selegiline, dopamine, pergolide and bromocriptine were reported to block formation of aSyn fibrils and destabilize preformed aSyn fibrils in a dose dependent manner (Ono et al., 2007b; Jha et al., 2017) . Furthermore, selegiline was able to delay fibril formation mainly by interfering with early nuclei formation and, to a lesser extent, with fibril elongation (Braga et al., 2011 ). An established amyloid inhibitor, scyllo-inositol, which has completed a phase 2 randomized trial in mild and moderate AD with no significant primary efficacy outcomes, can also inhibit the aggregation of aSyn (Ibrahim and McLaurin, 2016) .
Epidemiological studies have revealed that therapeutic use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with reduced risk of developing PD. The NSAIDs, such as ibuprofen, aspirin, acetaminophen, meclofenamic acid sodium salt, sulindac sulfide, ketoprofen, flurbiprofen and diclofenac sodium salt inhibited the formation of aSyn fibrils and destabilized preformed aSyn fibrils (Hirohata et al., 2008) . Food and Drug Administrationapproved drug FTY720 (fingolimod, Gilenya) reduced aSyn pathology in transgenic A53T mice, suggesting its potential use in PD patients and others with synucleinopathy (Vidal-Martínez et al., 2016) . Pharmacological inhibition of Rho-associated protein kinase (ROCK) using the isoquinoline derivative Fasudil, a small molecule inhibitor already approved for clinical use in humans that can directly interacts with a-Syn, significantly reduced aSyn aggregation and attenuates aSyn pathology in transgenic A53T mice (Tatenhorst et al., 2016) . Rifampicin, a well-known antibiotic, inhibited oligomer formation of amyloid-b, tau, and aSyn, indicating its broad spectrum (Ono and Yamada, 2006; Umeda et al., 2016) .
Sex hormones, estriol, estradiol, estrone, androstenedione, and testosterone, significantly exert anti-aggregation and fibrildestabilizing effects (Hirohata et al., 2009 ). Melatonin, a secretory product of the pineal gland said to have antioxidant function, blocked aSyn fibril formation as well as destabilizing preformed aSyn fibrils. Further analysis showed melatonin was able to inhibit protofibril formation, oligomerization, and secondary structure transitions as well as decrease aSyn-induced cytotoxicity (Ono et al., 2012a) .
In recent years, we have also seen a considerable increase in the number of reports exploring short peptides as inhibitors of amyloid-based aggregation. Unlike small molecule inhibitors, short peptides can help us identify the sequence regions responsible for driving protein aggregation. Rezaeian et al. (2017) utilized database from protein data bank to search for sequences which adopt b structure and are identical or very similar to the regions of aSyn involved in aggregation and chose adjacent b strands of the found sequences as the peptide inhibitors of aSyn aggregation. Two of the predicted peptides, namely KISVRV and GQTYVLPG, were proved to be efficient in suppressing aggregation of aSyn in vitro. Moreover, KISVRV exhibited the ability to disrupt oligomers of aSyn.
As mentioned above, rigorous preclinical studies have revealed some potential small molecules and peptides that can be allowed to proceed to clinical trials. However, learning from the rifampicin study, clinical trial design should be optimized.
Lessons from trials on various neurodegenerative disorders
Alzheimer's disease (AD) is characterized by presence of cortical amyloid-beta (Ab) plaques, neurofibrillary tangles, gliosis, and neuronal loss. Immunization of patients with Alzheimer's disease with full-length amyloid-beta peptide Ab42 can clear amyloid plaques from the brain. However, the outcomes of early phase I randomized, placebo-controlled trial of immunization with Ab42 (AN1792, Elan Pharmaceuticals) were disappointing with no significant benefits in cognition despite a reduction in Ab plaques of AD patients (Holmes et al., 2008) . As Ab plaques results from sequential action of b-secretase and g-secretase on amyloid precursor protein, semagacestat, a small-molecule g-secretase inhibitor, was developed as a potential treatment for AD by Eli Lilly and Elan. A double-blind, placebo-controlled trial of semagacestat for treatment of AD, funded by Eli Lilly, reported semagacestat did not improve cognitive status, while patients receiving the higher dose had significant worsening of functional ability as compared with placebo. The trial was terminated before completion as semagacestat was associated with serious adverse events, including weight loss, skin cancers and infections (ClinicalTrials.gov number, NCT00594568) (Doody et al., 2013) .
Solanezumab, a humanized monoclonal antibody also developed by Eli Lilly, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. Acute and subchronic treatment with solanezumab of transgenic mice attenuated or reversed memory deficits with no incidence of cerebral amyloid angiopathy-associated microhemorrhages, a severe side effect associated with another monoclonal antibody bapineuzumab. Phase 2 studies in AD patients have shown acceptable safety profile with positive target engagement indication on cerebrospinal and plasma biomarkers (Imbimbo et al., 2012) . However, the first phase 3 trials of solanezumab for mild-to-moderate AD showed that the antibody failed to improve cognition or functional ability (EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683) (Doody et al., 2014) . Subsequent phase 3 study, EXPEDITION3, investigated solanezumab's effects in a mild AD population. All three EXPEDITION trials were negative for the primary outcome of change in cognition. A hypothesis put forward was that treatment effects would have been larger at an earlier disease stage because disease might have been too advanced even in patients with mild AD (Siemers et al., 2016) . Solanezumab is also being assessed in individuals with prodromal AD in the ExpeditionPRO trial (NCT02760602), which will be completed in April 2021, and in the A4 trial (NCT02008357) in people with amyloid plaques in their brains who might be at risk of memory loss and cognitive decline because of AD. Perhaps Solanezumab will prove to be effective in people who are at an earlier stage of AD than the participants in EXPEDITION3 (The Lancet Neurology, 2017).
Preliminary randomized, controlled trial showed therapy with rifampicin might have a therapeutic role in patients with mild to moderate AD (Loeb et al., 2004) . However the following multicenter, blinded, randomized, factorial controlled trial of rifampicin showed no effect in slowing the disease progression in AD patients (Molloy et al., 2013) . Clinical or biochemical evidence of efficacy of Curcumin C3 Complex ( ® ) in AD was not shown in a 24-week randomized, double blind, placebo-controlled trial (Ringman et al., 2012) .
Spinal and bulbar muscular atrophy (SBMA) is a hereditary motor neuron disease caused by the expansion of a polyglutamine tract in the androgen receptor. At present, there are no treatments for SBMA. In a phase 2 trial (randomized, placebo-controlled trial for 48 weeks, followed by open-label trial for an additional 96 weeks), leuprorelin suppressed the deterioration of neuromuscular impairment in SBMA by inhibiting the accumulation of pathogenic androgen receptors. Patients treated with leuprorelin acetate for 144 weeks exhibited significantly greater functional scores and better swallowing parameters than those who received placebo (Banno et al., 2009 ). However, in following large-scale multicentre, randomized, double-blind, placebo-controlled trial, 48 weeks of treatment with leuprorelin did not show significant effects on swallowing function in patients with SBMA, despite being well tolerated. It is said that efficacy of leuprorelin might be influenced by disease duration and further clinical trials should be carried out in subpopulations of patients (Katsuno et al., 2010) . In a recent natural history-controlled study, long-term treatment with leuprorelin acetate up to 84 weeks was reported to delay the functional decline and suppress the incidence of pneumonia and death in patients with SBMA (Hashizume et al., 2017) .
Metachromatic leukodystrophy (MLD) is an inherited lysosomal storage disease caused by arylsulfatase A (ARSA) deficiency. Patients with MLD exhibit progressive motor and cognitive impairment and die within a few years of symptom onset. A phase I/II gene therapy trial used a lentiviral vector to transfer a functional ARSA gene into hematopoietic stem cells from three presymptomatic patients who showed genetic, biochemical, and neurophysiological evidence of late infantile MLD. After reinfusion of the gene-corrected hematopoietic stem cells, the patients showed extensive and stable ARSA gene replacement, which led to high enzyme expression throughout hematopoietic lineages and in cerebrospinal fluid. The disease did not manifest or progress in the three patients 7e21 months beyond the predicted age of symptom onset . A subsequent ad-hoc analysis of data from the trial revealed eight patients, seven of whom received treatment when presymptomatic, had prevention of disease onset or halted disease progression as per clinical and instrumental assessment, compared with historical untreated control patients with earlyonset disease. Assessment performed up to the last follow-up showed six patients with gross motor performance similar to that of normally developing children (Sessa et al., 2016) .
Wiskott-Aldrich syndrome (WAS) is an inherited immunodeficiency caused by mutations in the gene encoding WASP, a protein regulating the cytoskeleton. Three children patients, who had been shown by genotyping to carry severe mutations in the X-linked WAS gene and who did not have compatible allogeneic donors, were enrolled in a phase I/II clinical trial. A lentiviral vector encoding functional WASP was used to genetically correct hematopoietic stem/progenitor cell from the patients. Following cell reinfusion, WASP expression was restored to near-physiological levels in the patients, resulting in immunological and hematological improvement and clinical benefit .
Disappointments in the AD and SBMA clinical trials and triumph in the gene therapy for MLD and WAS underscore the importance of starting treatment at prodromal stage before symptoms onset and signify the potential beneficial effect of early treatment.
A refined concept: aSyn dysregulation disease
Stroke risk factors include hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking, obesity and carotid artery disease. Stroke risk varies depending on these factors (Romero et al., 2008) . Hyperlipidemia is one of the worst risk factors of stroke. Several large randomized trials of statins, the HMG-CoA reductase inhibitors, have consistently demonstrated stroke relative risk reduction associated with lowering of lipid levels, despite variation in the agent and dose used across studies (UK Prospective Diabetes Study (UKPDS) Group., 1998; Athyros et al., 2002; Sever et al., 2003; Colhoun et al., 2004; Collins et al., 2004) .
Although hyperlipidemia has no symptoms, diagnosing and managing hyperlipidemia with lipid-lowering medications is a way to prevent the occurrence of stroke. As described above, SNCA, the gene responsible for expression of aSyn, is the most important genetic risk factors for PD. Moreover, aSyn accumulation is a key determinant of dopaminergic neuronal degenerative susceptibility in PD and is a feature of both familial and sporadic PD, as well as in DLB and MSA. In the same sense as treating hyperlipidemia in prevention of stroke, therapeutic intervention inhibiting the accumulation and propagation of aSyn should begin as soon as possible before neuronal damage gets extensive. Therefore, we bring in a refined concept of recognizing "the pathogenic state of abnormal accumulation of aSyn protein aggregates before occurrence of irreversible severe brain damage and symptom onset" as aSyn dysregulation disease (ASDD) to make early clinical intervention possible as pre-onset treatment is not ethically justified as standard practice at present (Fig. 3) .
Early detection and diagnosis of aSyn dysregulation disease
Early detection and diagnosis of ASDD is a prerequisite for timely intervention whereby the treatment gap can be closed. Nonmotor symptoms, such as olfactory dysfunction (hyposmia), rapid eye movement (REM) sleep behavior disorder (RBD) and autonomic dysfunction that precede the onset of motor dysfunction are thought to be related to deposition of aSyn in lower brainstem or peripheral nerves, which occur earlier than in SN. RBD is parasomnia manifested by vivid dreams associated with dream enactment behavior due to the loss of normal atonia during REM sleep. Cohort studies from sleep disorder clinics, report that 40%e65% RBD patients develop neurodegenerative syndrome in 10 years, and the median latency between RBD onset and the diagnosis of PD is ranged from 12 to 14 years (Schenck et al., 1996; Schenck and Mahowald, 2003) . In a clinicopathological study, among 170 neurodegenerative disorders associated with RBD, 94% were synucleinopathies (Boeve et al., 2013) , indicating high RBDsynucleinopathy association. The extremely high risk and long latency to intervene makes potential for RBD as a marker of ASDD and RBD patients the ideal candidate for neuroprotective therapy against synucleinopathies (Iranzo et al., 2010) .
Many PD patients show a decline in odor identification and discrimination, in which the degree correlates with the disease duration and severity (Doty et al., 1992; Hawkes et al., 1997; Deeb et al., 2010; Siderowf et al., 2005) . Supporting this finding, olfaction is reported to be impaired in SNCA, parkin, PINK1, LRRK2 and ATP13A2 and glucocerebrosidase gene (GBA) mutations related PD (Silveira-Moriyama et al., 2010; Saunders-Pullman et al., 2010) . A study done by Sengoku et al., (2008) reported high incidence of Lewy-bodies-related a-synucleinopathy in the aging human Fig. 3 . Phases showing progressive development in PD with a combination of traditional and refined concepts. Aging, genetic and environmental factors are the important risk factors that cause PD and these factors vary from person to person. In the preclinical phase, neurodegeneration begins but no clinical signs or symptoms of PD are present. In the prodromal phase, nonmotor manifestations including olfactory, sleep and autonomic changes are detectable. A prodromal phase has a more than 10 years latency that precedes the clinical onset of PD. The new concept is to recognize "the pathogenic state of abnormal accumulation of aSyn which spans between the onset of neurodegeneration and manifestation of the typical motor symptoms" as aSyn dysregulation disease, allowing aSyn targeting based clinical intervention to be applied to reduce aSyn protein levels and aggregates in the early stage and thereby preventing, halting or delaying disease onset. olfactory bulb, which extends from the periphery to the anterior olfactory nucleus. Olfactory bulb a-synucleinopathy has high specificity and sensitivity for Lewy body disorders. The sensitivities and specificities were, respectively: 95 and 91% for PD versus elderly control; 97 and 91% for DLB versus elderly control (Beach et al., 2009 ). Initiation of Lewy body pathology distribution in olfactory bulb may reflect the relationship between hyposmia and PD and the potential of olfactory dysfunction being used as a biomarker of ASDD.
Cardiac sympathetic denervation, a symptom of autonomic dysregulation, occurs in PD and DLB, accounting for reduced cardiac uptake of meta-iodobenzylguanidine (MIBG) on [(123)I] MIBG myocardial scintigraphy even in the early stages. Degeneration of the distal axons of the cardiac sympathetic nerve precedes loss of their mother neurons in the paravertebral sympathetic ganglia (Orimo et al., 2007) . aSyn aggregates observed in the distal axons of the cardiac sympathetic nerve are associated with disappearance of TH-immunoreactive axons. Cardiac sympathetic denervation is closely related to the presence of LBs in a wide range of neurodegenerative processes, implying that reduced cardiac uptake of MIBG could be a potential biomarker for ASDD (Orimo et al., 2008) .
Assessment of cardiac sympathetic function and olfactory sensitivity in 40 non-demented patients with idiopathic PD and age-matched controls by MIBG uptake and Odor Stick Identification Test for Japanese, respectively showed that the olfactory system degenerated in parallel with cardiac sympathetic nervous system denervation in early PD patients, but that the two systems may degenerate at different rates in patients with more advanced PD (Iijima et al., 2010) . Combination of olfactory testing and MIBG myocardial scintigraphy can be a diagnostic indicator for ASDD.
Constipation, a well-known symptom in PD, was in fact part of James Parkinson's original description of the disorder and potentially appears as early as more than 20 years before the onset of the motor signs. Honolulu Heart Program study that involves 6790 men age 51e75 years old showed those who had less than one bowel movement per day had an odds ratio of 2.7 for developing PD compared to men who had one bowel movement per day (Abbott et al., 2001) . A retrospective analysis of routine colon biopsies has recently shown aSyn deposits in the enteric nervous system 2e5 years before the clinical onset of PD, suggesting a useful and accessible biomarker (Shannon et al., 2012) .
Body fluid-and tissue-based biomarkers may be potentially helpful in diagnosing ASDD. Cerebrospinal fluid (CSF) is an excellent source for identifying biomarkers for neurological diseases affecting the CNS as it remains in direct contact with the CNS and reflects the neurochemical state under different physiological and pathological conditions. In addition to CSF, protein contents from blood, serum, plasma, saliva and urine can also be analyzed (Sharma et al., 2013) .
Studies have demonstrated reduced CSF aSyn in patients with advanced PD diseases (Kroksveen et al., 2011; Mollenhauer and Trenkwalder, 2009; Shi and Zhang, 2011) . However the overall results are inconsistent (Leonidas, 2012) . The diagnostic sensitivity of CSF aSyn ranged from 70% to 93%, but the specificity is much lower for distinguishing PD from other movement disorders. Besides monomeric aSyn species, oligomeric aSyn, measured by a specific ELISA method, was higher in PD compared with control CSF (Tokuda et al., 2010) , supporting the identification of soluble oligomeric aSyn in DLB brain tissue (Paleologou et al., 2009 ). However, it remains unknown to what extent monomeric and oligomeric aSyn levels reflect the aSyn's condition in the CNS or if it correlates with disease progression or severity (Schmid et al., 2013) . Furthermore, there is a definite need for validation of the potential CSF biomarkers in preferentially pathologically confirmed cohorts and to account for inter-laboratory variability in multiple centers. Fairfoul et al. (2016) developed a novel real-time quakinginduced conversion (RT-QuIC)-based assay to detect aSyn aggregation in brain and CSF from DLB and PD patients. With both conditions underpinned by the neuropathological deposition of an aggregated form of aSyn which is released into the CSF, they exploited the ability of the aggregated aSyn to induce further aggregation of nonaggregated aSyn in a cyclic manner to develop a technique that can detect abnormal CSF aSyn in DLB and PD with a sensitivity of 92% and 95%, respectively, and 100% specificity. More uniquely, three RBD patients at high future risk of developing a Lewy body disorder gave a positive RT-QuIC response. Future work focusing on test validation in a larger cohort of RBD patients, followed by ongoing longitudinal assessment, will test the usefulness of this new approach in risk stratifying prodromal individuals with ASDD most at risk of early PD conversion in whom neuroprotective therapies might be trialed.
Accumulation of extensively phosphorylated aSyn within mucosal and submucosal nerve fibres, and ganglia have been reported in the biopsy samples of PD patients collected up to 8 years prior to the onset of motor symptoms. All patients with positive biopsies had early autonomic symptoms and all controls were negative. This study demonstrates that accumulation of aSyn in the gastrointestinal tract is a highly specific finding that could be used to detect ASDD (Hilton et al., 2014) . Malek et al. (2014) published a systematic review of available evidence from a total of 49 studies to determine the utility of aSyn as a peripheral biomarker of PD. Peripheral tissues such as colonic mucosa showed a sensitivity of 42e90% and a specificity of 100%; submandibular salivary glands showed sensitivity and specificity of 100%; skin biopsy showed 19% sensitivity and 80% specificity in detecting aSyn pathology. CSF aSyn had 71e94% sensitivity and 25e53% specificity for distinguishing PD from controls. Plasma aSyn had 48e53% sensitivity and 69e85% specificity. Neither plasma nor CSF aSyn is presently a reliable marker of PD. Development of RT-QuIC-based assay makes it feasible to detect aSyn aggregation in CSF with higher sensitivity and specificity. aSyn in solid tissue samples of the enteric and autonomic nervous system, also offer some potential as a surrogate marker of brain synucleinopathy.
Conclusion
The need for early treatment is perhaps best highlighted in the recent clinical trial failures. Pre-onset treatment is not ethically justified as standard practice at present. The concept of coining new term "ASDD" to the "pathogenic state of abnormal aSyn accumulation in brain prior to occurrence of irreversible severe brain damage and symptom onset" permits early antibody-, vaccine-, antisense-oligonucleotide-and small molecule-based clinical intervention to lessen aSyn protein levels and aggregates in prodromal individual at risk. This can likely prevent, halt or delay disease onset which greatly benefit the patients. Development of new biomarkers may fill gaps in our ability to obtain early diagnosis and help to identify patients that are more likely to respond favorably to a given therapy. Existing potential biomarkers for ASDD as briefly reviewed in this paper need to be better characterized and validated in the aspects of sensitivity, specificity and variability, preferably in larger cohorts and multiple centers. The list of biomarkers will undoubtedly flourish in the near future with progress of proteomics strategy and new knowledge on the pathogenic processes involved in aSyn accumulation.
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